U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07790783) titled 'Phase 1 Clinical Study of GenSci164 Injection' on Aug. 14.
Brief Summary: This is a single-center, randomized, double-blind, placebo-controlled, single-dose escalation Phase 1 clinical study to evaluate the safety, tolerability, PK profile, PD profile, and immunogenicity of GenSci164 after a single subcutaneous injection in healthy adult participants in China.
Study Start Date: Aug. 24
Study Type: INTERVENTIONAL
Condition:
Healthy Adult Trial Participants
Intervention:
DRUG: GenSci164 Injection
6 dose cohorts
DRUG: Placebo
6 dose cohorts
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Changchun GeneScience Pharmaceutical ...